TriSalus Life Sciences Appoints Liselotte Hyveled to its Board of Directors

TriSalus Life Sciences Inc. (Nasdaq: TLSI), an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced today the appointment of Liselotte Hyveled to its Board of Directors. Ms. Hyveled brings over two decades of experience stimulating scientific innovation and advancing pharmaceutical pipelines through research and development excellence.

“We are thrilled to welcome Liselotte to the TriSalus Board of Directors as we commercialize the TriNav Infusion System and progress our pipeline through key milestones in 2024 and beyond,” said Mats Wahlstrom, TriSalus Chairman of the Board. “Her wealth of experience and strategic insights will be instrumental in shaping TriSalus' long-term vision of pioneering innovative treatments for liver and pancreatic cancers. We eagerly anticipate Liselotte's contributions to our continued success.”

“Liselotte's extensive background in fostering patient-centric innovations, strategic planning, and the integration of technology and therapeutics will be invaluable assets as we navigate TriSalus’ growth trajectory,” Mary Szela, President and CEO of TriSalus. “Her guidance will be pivotal in our efforts to expand and scale operations while expediting the development of our technology and therapeutic pipelines.”

Ms. Hyveled is a seasoned executive with over two decades of successfully implementing innovative solutions for challenging chronic diseases within a rapidly changing, highly competitive R&D environment. Currently serving as the Chief Patient Officer at Novo Nordisk, she is responsible for ensuring the integration of patient needs and perspectives into the company's decision-making processes and operations, from inception to commercialization. Ms. Hyveled's tenure at Novo Nordisk has been marked by numerous leadership positions and contributions, reflecting her commitment to R&D excellence, breakthrough innovation and advancing patient-centric solutions. She has initiated several social responsibility initiatives at Novo Nordisk with a focus on neurodiversity, disabilities and generational intelligence. Ms. Hyveled holds a Master of Pharmacy Science from Copenhagen University and a Master of Medical Business Strategies from Copenhagen Business School.